Diabetes, Obesity and Metabolism
Издатель: Wiley · ISSN 14628902 · 81 статей
-
Global Trends and Exposure Profiling of Early‐Onset Type 2 Diabetes: An Ecological Analysis Using Machine Learning
ABSTRACT Background Early‐onset Type 2 diabetes (EOT2D) is an increasing global health concern. We examined global trends in EOT2D incidence and identified robust population‐level exposure correlates. Methods Using the data from the GBD...
-
Two‐Year Trajectories of DIAL2‐Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL‐STEP Study
ABSTRACT Aims To describe observed clinical changes and trajectories of DIAL2‐predicted cardiovascular risk during 24 months of oral semaglutide, empagliflozin or combination treatment. Materials and Methods This retrospective cohort...
-
Genetically Predicted β‐Hydroxybutyrate and Coronary Atherosclerosis: Mendelian Randomization and APOE‐Associated Transcriptomic Signatures in Human Atherosclerotic Plaques
ABSTRACT Aims Ketone bodies are implicated in cardiovascular metabolism, yet the contributions of β‐hydroxybutyrate (BHB), acetoacetate and acetone to coronary atherosclerosis remain unclear. Methods We integrated Mendelian...
- Continuous Glucose Monitoring in Obesity Without Diabetes: An Unnecessary Gadget or a Gateway to Precision Care?
-
Diabetic Ketoacidosis: Systematic Review and Meta‐Analysis
ABSTRACT Aims Diabetic ketoacidosis (DKA) remains a major cause of diabetes‐related morbidity and mortality worldwide, yet evidence on its management and clinical outcomes across healthcare settings remains limited. We conducted a...
-
Diabetes Type and Perinatal Adverse Outcomes Among Women in Pregnancy and Neonates in Japan: A Cohort Study Using a Large‐Scale Database
ABSTRACT Aims To compare maternal and neonatal outcomes across gestational diabetes, preexisting diabetes, overt diabetes in pregnancy and normoglycaemia in Japan. Materials and Methods Using the JMDC claims database, we conducted a...
-
Longitudinal Associations of Changes in Body Mass Index and Waist‐to‐Height Ratio With Cardiometabolic Risk Factors: Sex‐Specific Analyses in UK Biobank
ABSTRACT Aims To examine associations of within‐person changes in body mass index (BMI) and waist‐to‐height ratio (WHtR) with cardiometabolic outcomes, characterise dose–response non‐linearity and investigate effect modification by sex....
-
Development and Validation of 10‐Year Prediction Models for Cardiovascular, Kidney and Metabolic Events Among Chinese Patients With Prediabetes in Hong Kong
ABSTRACT Aims Risk stratification can support frontline doctors and patients by enabling care and empowering early prevention of cardiovascular, kidney and metabolic disease. We aimed to develop and validate 10‐year prediction models...
-
Birthweight and Glucose Tolerance Status Are Associated With Organ Sizes in Older Adults
ABSTRACT Aims Low birthweight is a risk factor of Type 2 diabetes and cardiovascular disease. Organ size is related to organ function and disease, but few studies have examined cardiometabolic organ sizes in relation to birthweight and...
- Persistent Gaps in Semaglutide and Tirzepatide Prescribing Among Adults With Class III Obesity Without Type 2 Diabetes
-
Effectiveness of GLP‐1 RAs and SGLT‐2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) are both recommended as second‐line treatments for individuals with Type 2 diabetes and obesity, but long‐term...
-
GLP‐1 Receptor Agonists Use in Patients With Prior Psychotropic Treatment: A Nationwide Cohort Study
ABSTRACT Aims Psychotropic medications are frequently associated with weight gain and metabolic syndrome. While GLP‐1 receptor agonists (GLP‐1RAs) have generated interest for managing these adverse effects, their current uses in...
-
Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform
ABSTRACT Aims Finerenone was approved in China in 2022 for adult patients with chronic kidney disease (CKD) associated with Type 2 diabetes (T2D). This study aimed to characterize Chinese patients with CKD and T2D who initiated...
-
Effects of GLP‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis
ABSTRACT Objectives Hyperuricemia and gout are common but underappreciated comorbidities in Type 2 diabetes (T2D), obesity and chronic kidney disease (CKD). We aimed to quantify the pooled effects of glucagon‐like peptide‐1 receptor...
-
Weaker or Just Lighter? Monitoring Strength and Function, Not Just Lean Mass, During GLP‐1 Weight Loss
ABSTRACT Aims Body‐composition studies of GLP‐1‐based therapy report how much of the weight lost is lean mass, not whether the patient is getting weaker. This review asks how to monitor strength and function during treatment. Materials...
- Lean Body Mass During GLP‐1‐Based Therapy and the Potential Role of Dietary Protein: Evidence From Energy‐Restriction Trials
-
Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT‐1 Randomized Controlled Trial
ABSTRACT Aims Glucagon‐like peptide‐1‐based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide...
- The Growing Incretin Mimetic Therapy Revolution and Potential Ophthalmic Risks: Need for Clinicians to Focus on Ophthalmic Surveillance
-
Metformin and Severe Post‐COVID‐19 Outcomes Among Individuals With Diabetes Mellitus
ABSTRACT Aims We evaluated the relationship between metformin, one of the most commonly prescribed medications for individuals with diabetes, and COVID‐19 sequelae. Materials and Methods We evaluated a retrospective cohort of...
-
Differences in the Glucose Management Indicator Between Continuous Glucose Monitoring Systems
ABSTRACT Aim The glucose management indicator (GMI) estimates HbA1c from continuous glucose monitoring (CGM)‐derived mean glucose. We assessed whether this relationship differs between contemporary CGM systems. Materials and Methods In...
-
Can a Single Maximally Fortified Food Improve Glycaemia in Type 2 Diabetes? Randomised Crossover Trial of High‐Fibre High‐Protein Bread
ABSTRACT Objective To examine the effects of a maximally fortified high‐fibre high‐protein bread on glycaemia in free‐living adults with Type 2 diabetes. Research Design and Methods Participants were provided commercially produced...
- Beyond the Scale: Psychological and Behavioural Considerations Following GLP‐1 Receptor Agonist Treatment Discontinuation
-
Cardiometabolic, Physiological and Objective‐Sleep Responses to Transcendental Meditation: Secondary Analysis of a Randomised Controlled Trial Among University Staff
ABSTRACT Background and Aims Chronic stress contributes to cardiometabolic risk, and stress‐reduction interventions have been proposed to improve stress‐sensitive physiology and cardiometabolic health, though evidence remains...
- Correction to ‘Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis’
-
Association Between Weight Loss on Incretin‐Based Therapy and Cardiovascular Outcomes and Mortality: A Systematic Review and Meta‐Regression
ABSTRACT Aims The primary aim was to evaluate, using aggregate‐data meta‐regression, whether body weight loss induced by incretin mimetic therapy is associated with reductions in three‐point major adverse cardiovascular events ( 3P ‐...
-
Bleeding and Thromboembolic Outcomes Following GLP‐1 Receptor Agonist Initiation in Patients With Type 2 Diabetes and Atrial Fibrillation Receiving Direct Oral Anticoagulants: A Target Trial Emulation
ABSTRACT Aims Patients with atrial fibrillation (AF) and Type 2 diabetes (T2D) require coordinated stroke prevention and metabolic risk management. Direct oral anticoagulants (DOACs) are standard for stroke prevention, while...
-
Early Changes in Peripancreatic Mesenteric Fat Beyond Weight Loss Predict Durability of Hepatic Improvements in MASLD
ABSTRACT Aims Various visceral adipose tissue depots exhibit heterogeneous metabolic properties. This study aims to explore whether specific abdominal fat compartments differentially predict loss of sustained treatment response to...
-
β‐Cell Recovery Patterns With Initial Combination Versus Stepwise Therapy in Newly Diagnosed Type 2 Diabetes: TRIPLE‐AXEL Post Hoc Analysis
ABSTRACT Background Early intensive therapy may preserve β‐cell function in newly diagnosed Type 2 diabetes mellitus (T2DM), but whether different early treatment strategies produce distinct patterns of β‐cell functional recovery...
-
Reproductive Outcome Registration in Phase 3 Weight‐Management Pharmacotherapy Trials: A Cross‐Sectional Meta‐Research Study
ABSTRACT Aims To quantify registered reproductive outcome measures in women and men in adult Phase 3 weight‐management pharmacotherapy trials and compare them with registered body‐composition measures. Materials and Methods...
- Correction to ‘Young Adults With Nonalcoholic Fatty Liver Disease, Defined Using the Fatty Liver Index, Can Be at Increased Risk of Myocardial Infarction or Stroke’